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Clinical, histologic and serologic evaluation of patients 
with acute non-A-E hepatitis in north-eastern Brazil: 
is it an infectious disease? 
Raymundo ParanB,(1,2) Liana Codes,(1,2) Zilton Andrade,c3) Luiz A. R. de Freitas,c3) 
Rog&-io Santos-Jesus,(1,2) Mitermayer Reis,c3) Helma Cotrim,(1,2) Simone Cunha(1,2) 
and Christian Trepoc4) 
Non-A-E hepatitis and acute cryptogenic hepatitis are the names given to the disease of patients with clinical 
hepatitis, but in whom serologic evidence of A-E hepatitis has not been found. Over a period of 8 years, we evaluated 
in Brazil 32 patients who fulfilled the criteria for this diagnosis in order to determine patterns of the clinical illness, 
laboratory parameters, or histologic features. Each patient was subjected to virologic tests to exclude A-E hepatitis 
and cytomegalovirus/Epstein-Barr virus infection. Drug-induced hepatitis and autoimmune disease were also 
excluded. Wilson’s disease was excluded in young patients. The course of the disease was clinical/biochemical 
recovery in 3 months in 25 patients and persistent alanine aminotransferase (ALT) elevation in 7 patients. Three of 
these had chronic hepatitis, and one had severe fibrosis on liver biopsy. During the acute illness, mean peak ALT was 
1267 IU/L, bilirubin was 4.0 mg/dL, and ferritin was 1393 IU/mL. GB virus type C (GBV-C) was found in six patients, 
and TT virus (TTV) in five patients. We conclude that, in Brazil, non-A-E hepatitis probably originates from still 
unidentified viruses. The course of the disease and the histologic patterns are similar to those recorded for known 
viruses. Continuous survey for the specific etiologic agents is needed. 
Int J Infect Dis 2003; 7: 222-230 
INTRODUCTION 
Despite major progress in the development of new 
diagnostic tools for the etiologic determination of viral 
hepatitis, 20-30% of acute viral hepatitis cases remain 
unexp1ained.i 
The existence of acute hepatitis of undetermined 
etiology suggests the possibility of infection by unknown 
viruses or autoimmune disease in the absence of the 
characteristic autoantibodies. Therefore, while this 
enigma remains, the disease is alternatively designated 
as acute cryptogenic hepatitis or non-A-E hepatitis. 
The clinical picture and the prognosis of this disease 
vary from mild forms with minimal symptoms to acute 
liver failure. Some cases may become chronic, with a 
potential to progress to cirrhosis.3,4 
The new viruses, including GBV-C and TTV, do not 
seem to account for this disease, since the prevalence of 
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these viral agents in the asymptomatic population and 
their prevalence in acute non-A-E hepatitis are not 
significantly different from that observed in well-defined 
etiologic groups. Thus, clear evidence for their patho- 
genicity is still lacking.5,6 
Owing to the wide variability in the clinical aspects 
and in the biochemical and histologic characterization of 
this syndrome, it is important to better define the clinical 
patterns and to explore whether different etiologies may 
exist. 
Thus, the aim of this study was to describe the 
clinical, biochemical and histologic aspects of acute non- 
A-E hepatitis in Salvador-BA, north-eastern Brazil, and 
to evaluate the role of GBV-C, TTV and autoimmunity 
in the etiology of these selected cases. 
PATIENTS AND METHODS 
From March 1992 to May 2000,62 consecutive patients 
fulfilling the criteria of acute non-A-E hepatitis were 
evaluated. From these, 32 were enrolled in a prospective 
cohort study. The duration of follow-up ranged from 6 to 
96 months (32 + 16 months). A diagnosis of acute non- 
A-E hepatitis was made in patients with a clinical 
picture of acute hepatitis and alanine aminotransferase 
(ALT) level higher than 10 times the upper normal limit. 
Patients with a history of potentially hepatotoxic drug 
abuse, congestive heart failure, biliary obstruction and 
alcohol consumption higher than 40 g of ethanol daily 
were excluded. 
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A confidential questionnaire was filled out for the 
evaluation of clinical and epidemiologic data. Parenteral 
risks were also evaluated, such as dental treatment in the 
last 6 months, tattooing, blood transfusion and use of 
blood-derived products, and intravenous drug use 
(IVDU). Further data considered were living conditions, 
past personal or family hepatitis infections, sexual 
behavior, and alcohol consumption. 
The serologic criteria used to accept non-A-E 
hepatitis were: virologic profile negative for anti-hepatitis 
A virus (HAV) IgM, anti-HBc IgM, hepatitis B surface 
antigen (HbsAg), anti-hepatitis E virus (HEV), anti- 
hepatitis C virus (HCV), anti-cytomegalovirus (CMV) 
IgM, anti-Epstein-Barr virus (EBV) IgM, HCV RNA, 
autoantibodies (ANA, ASMA, anti-LKM-I and AMA) 
with titers lower than l/80, and negative Wilson’s disease 
screening in patients younger than 25 years. 
Viral hepatotropic markers were determined using 
commercial kits (Abbott, Chicago, IL, USA). CMV IgM 
and EBV IgM were tested in patients with none of the 
above-mentioned serologic markers for hepatotropic 
viruses, using Kits from BioMerieux (Lyon, France). 
Patients who tested positive for CMV and EBV were 
excluded. 
HCV RNA was measured during the acute phase by 
two duplicate determinations at 15 and 30-day intervals, 
according to the method of Li et a1.7 
Autoantibodies were determined by indirect immu- 
nofluorescence during the acute phase and repeated 
from 30 to 90 days during follow-up. 
Serum ferritin was determined in all patients during 
the acute phase and from 30 to 90 days during follow- 
up, using the chemiluminescence method of Sanofi- 
Pasteur (Paris, France). For comparison with known 
hepatitis viruses, we determined ferritin levels in stored 
serum samples from 54 patients with acute hepatitis A, 
52 with acute hepatitis B, and 13 with acute hepatitis C. 
Biochemical workups were carried out during the 
acute phase and every 1.5 days up to the third month. All 
analyses were then performed monthly up to the sixth 
month and then every 6 months. 
GBV-C RNA was determined by PCR,s and TTV 
DNA was determined as previously described by 
Biagini et a1.9 
A liver biopsy was proposed during the acute phase, 
and always performed, at the latest, 6 months after 
disease onset in cases with still elevated ALT. 
Statistical analysis 
Dichotomous variables were analyzed by the chi-square 
or Fisher exact test, when necessary. Group mean 
differences were compared by the Mann-Whitney test. 
The Spearman correlation coefficient was used to test 
the association between ALT and ferritin levels. All tests 
were performed using SPSS software, with the level 
of significance set at two-tailed alpha = 0.05 for all 
statistical tests. 
RESULTS 
During the selection period, 62 patients were initially 
diagnosed as having acute cryptogenic hepatitis. Of 
these patients, 32 were admitted to the cohort study; 15 
(47%) were females, and 17 (53%) were males. Patients 
who lived outside Salvador city and patients who did not 
consent to participate in the study were not included in 
this cohort. Their average age was 33.8 (k27.3) years. 
Medical visits were scheduled every month up to 
6 months, and every 3 months thereafter. 
After filling in a confidential questionnaire, 77% 
reported sexual activity, while sexual promiscuity and/or 
sexually transmitted diseases (STDs) were observed 
only in nine patients (28%). Parenteral exposure was 
found in six patients (19%). Five of them reported 
dental treatment in the previous 6 months, and one 
admitted to IVDU. None of the patients had a history of 
blood transfusion or tattooing (Table 1). 
Serum samples were collected on the occasion of 
each medical visit for biochemical determinations, and 
aliquots were stored at -70°C for PCR assays. 
Different signs and symptoms of acute liver disease 
motivated the patients to seek medical care. A brief 
prodromic phase with arthralgia and exanthema was 
reported in 10 patients (31%). Seventeen patients 
(53%) became icteric, while nine (28%) showed ‘nausea’ 
and/or vomiting, leading to the diagnosis of acute 
hepatitis. Fever was uncommon, being observed in only 
11% of the subjects (Figure 1). 
All patients became asymptomatic within 3 months 
after the onset of the disease. Most of them recovered 
within a few weeks after disease onset. 
During the acute phase (first 15 days), average ALT 
and bilirubin levels were 1267 (k1048) IU/L and 4.0 
(k5.2) mg/dL, r espectively. At this same time, serum 
ferritin reached an average Ievel of 1393 (~743) IU/mL 
and fell rapidly after 30-90 days (Table 2). For the sake 
of comparison, we measured retrospectively in stored 
sera the serum ferritin levels of patients with acute 
hepatitis caused by known hepatotropic viruses (HAV, 
Table 1. General characteristic of the cohort 
Characteristics 
Age (mean, years) 
Gender 
33.8 (k27.3) 
15 F (47%) 
17 M (53%) 
Parenteral risks 
Dental care 
Blood transfusion 
IVDU 
Tattooing 
Household contact hepatitis patients 
Sexual activity 
Promiscuity and/or STD 
Alcohol abuse (~40 g/day) 
5 (16%) 
0 
1 (3%) 
0 
5 (16%) 
24 (77%) 
9 (28%) 
11 (34%) 
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Figure 1. Signs and symptoms during the acute phase in patients with non-A-E hepatitis. 
Table 2. Biochemical tests during the acute and convalescence 
phases 
Test Acute phase Convalescence 
MeadRange Mean 
ALT (I U/L) 1267 I irIO 64.7 
Bilirubin (mg/dL) 4.0 / 25.2 0.93 
Ferritin (IU/mL) 1393 I +743 361.0 
HBV, HCV). Serum ferritin was present at levels of 522 
(+270) IU/mL, 405 (+220) IU/mL, and 886 (332) IU/mL, 
respectively. Serum ferritin was significantly higher in 
acute non-A-E cases than in cases of known etiology 
(Figure 2). 
In order to establish a correlation between ferritin 
and ALT levels, we used the Spearman correlation 
coefficient. However, no statistical significance was 
observed (Figure 3). 
Low titers of autoantibodies were found in 7/32 
(22%) of the acute-phase cases, which subsequently 
returned to normal within 3 months after disease onset. 
Six patients (19%) had GBV-C RNA in their serum, 
while 5/32 (16%) were found to be positive for TTV 
DNA. No clinical, histologic or biochemical peculiarities 
were found in GBV-C- or TTV-positive cases compared 
to patients with no GBV-C/TTV infection. In addition, 
only one patient who reported parenteral exposure 
(IVDU) was TTV -DNA- and GBV-C RNA-positive. 
During the acute phase, 5 of the 32 patients gave 
consent for a liver biopsy. The histopathologic study 
always confirmed the pattern of acute hepatitis of a pre- 
sumably viral nature. Extensive necrosis with portal- 
portal and portal-centrolobular vein bridges were 
observed in two patients, but both spontaneously 
recovered (Figures 4-6). Other features compatible 
with acute viral hepatitis were also observed, such as 
hepatocellular necrosis, infiltration of mononuclear 
inflammatory cells, and apoptotic bodies. 
During follow-up, 7/32 (22%) patients exhibited 
elevated ALT levels 6 months after the acute disease. 
Whenever ALT levels fluctuated between two and six 
times above the upper normal limit, these patients were 
considered to be suffering from chronic non-A-E 
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Figure 2. Comparison of acute-phase ferritin levels between known viral hepatitis and non-A-E cases. 
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Figure 3. Correlation between ALT and ferritin during the 
acute phase of non-A-E hepatitis cases. 
hepatitis. Comparison between chronic and resolved 
cases showed no difference regarding either the possible 
transmission route or ALT and bilirubin levels during 
the acute phase (Table 3). 
Histopathology revealed a chronic hepatitis pattern 
of variable activity with variation of the degree of 
fibrosis in five of the above patients. Mild-to-moderate 
steatosis was present in four patients (Figures 7 and 8). 
Remarkably, Mallory bodies and steatosis were 
observed in one patient with no history of alcohol intake 
and no risk factors for non-alcoholic steato-hepatitis 
(NASH). 
Conversely, one patient had minimal hepatic lesions 
3 years after acute hepatitis, although he presented 
persistently elevated ALT levels (Figure 9). 
These patients were treated with corticosteroids 
when chronic hepatitis was detected by liver biopsy or 
when clinical/biochemical deterioration was evident. 
Only one patient had a biochemical response after 
corticosteroid therapy. 
DISCUSSION 
The etiology of acute sporadic non-A-E hepatitis still 
remains completely unknown. Reports regarding 
clinical presentation and chronicity rate are conflicting, 
pointing to the necessity of further descriptive studies, 
mainly those with long-term follow-up after diagnosis 
was established during the acute phase.lO 
In the USA, a pivotal sentinel study found only 4% 
of acute non-A-E hepatitis cases, and 25% of these 
patients with non-A-E hepatitis had parenteral trans- 
mission risks.li On the other hand, non-A-E hepatitis 
seems to be more common in Greece, where many 
severe forms of the disease have been reported.12 Our 
group has already demonstrated that sporadic acute 
non-A-E hepatitis is the most common entity among 
acute cases of non-A non-B hepatitis at referral liver 
units in north-eastern Brazil, suggesting that this disease 
is quite common in this region and could be of viral 
origin.13 Another study from Argentina showed a broad 
spectrum of clinical presentation in 62 acute non-A-E 
hepatitis cases, and reported that two patients had 
traveled to Brazil before developing acute hepatitis.14 
Figure 4. Extensive necrosis with portal-portal bridges, during the acute phase. H&E, x20. 
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Figure 5. Extensive necrosis with portal-portal and portal-centrilobular vein bridges, during the acute phase. H&E, x10. 
Table 3. Biochemical parameters during the acute phase in 
patients with resolved and non-resolved acute non-A-E 
hepatitis. 
Characteristics 
ALT (I U/L) 
Bilirubin (mg/dL) 
Chronic Resolved P 
(mean/range) (mean/range) 
(n = 07) (n = 25) 
1074.4 + 988.1 1464.0 i 1812.6 0.54 
4.7 * 4.4 3.4 f 3.0 0.22 
These data suggest that non-A-E hepatitis is a 
heterogeneous disease, probably common in South 
America, perhaps with regional peculiarities. 
The lack of consensus about the diagnostic criteria 
used to define acute non-A-E hepatitis may account for 
the contrasting results reported in different studies, 
mainly in those from liver transplantation centers, where 
more severe cases prevail.i5,16 
Many viruses have been proposed as causative 
agents of acute non-A-E hepatitis, but definitive 
confirmation is still lacking. A togavirus-like particle was 
identified by electron microscopy, but no experimental 
reproduction of the disease has been rep0rted.l’ A 
paramixovirus has also been proposed as the etiologic 
agent of the giant cell non-A-E hepatitis, but this seems 
to be a rare disease, and there is no proof of a cause- 
effect relationship. I8 Recently, hantavirus infection was 
associated with some cases of non-A-E hepatitis in 
China,19 and a hepatitis with fecal-oral transmission was 
described in India.20 
In our cases, no features compatible with hantavirus 
infection were seen. Also, we did not obtain epidemio- 
logic data that might suggest a disease transmitted by 
the fecal-oral route. 
Recently, a new virus called GBV-CYHGV was 
thought to be implicated in some cases of non-A-E 
hepatitis, but data are conflicting. While some authors 
suggest that GBV-C can cause liver injury, many others 
have demonstrated that most GBV-C carriers have no 
liver injury. 21 Furthermore, GBV-C co-infection in 
patients who are carriers of HBV and HCV does not 
seem to influence the underlying liver disease.22 Of our 
cases, only 19% were positive for GBV-C RNA, and 
there were no clinical, biochemical or epidemiologic 
peculiarities in GBV-C-positive patients. 
More recently, a circovirus called TTV and other 
related viruses were proposed to cause non-A-E 
hepatitis. This putative hepatotropic virus may also be 
transmitted by the fecal-oral route.23 Later epidemio- 
logic studies have shown that this new agent is highly 
prevalent in Japanese and European populations, even 
in patients free from liver disease.24 At present, TTV 
cannot be considered a causative agent of hepatitis, even 
though it can be abundant in liver tissue. In our cases, 
TTV DNA was found in only a few patients, in contrast 
to the results of the Japanese and European studies.25-28 
This finding could be partially explained by previous 
exposure to this virus, which could generate a long-term 
immunologic response. As TTV seems to be also trans- 
mitted by the fecal-oral route, we may speculate that 
our population is massively exposed to this agent before 
adult life, and retains protective antibodies.5 Alternatively, 
the detection method used in our laboratory for TTV 
diagnosis may not be sensitive enough, and is genotype- 
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Figure 6. Mononuclear cell infiltrate in a 32-year-old patient 6 months after acute hepatitis onset. H&E, x40. 
Figure 7. Portal tract inflammatory infiltrate with piecemeal necroses, 8 months after acute disease. H&E, x20. 
dependent. This fact could explain the low prevalence of liminary.29 These viruses are closely related to TTV, and 
TTV DNA in our cases compared with the TTV seem to belong to the same family, proposed to be called 
prevalence described by other authors. circinoviridae.30 
Recently, other new DNA viruses, called SEN virus, On the other hand, the etiology of non-A-E hepa- 
HTLM virus, and the circinovirus-related Sanban/ titis could be unrelated to a viral agent. Hepatotoxic 
Yanban virus, were described in some patients with drugs are always mentioned as a possible cause, but our 
acute and chronic hepatitis, but the results are pre- protocol exhaustively excluded this possibility. In 
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Figure 8. Severe and progressing fibrosis 10 months after acute hepatitis (same patient as shown in Figure 5). H&E, x40. 
Figure 9. Mild portal inflammatory infiltrate 3 years after acute hepatitis. H&E, x40. 
addition, more than 50% of our patients presented a Many findings in our study strongly argue against 
prodromal phase, suggesting a virus-related disease. this possibility. The ratio of male/female patients was 
A seronegative variant form of autoimmune hepa- about 1, contrasting with that expected for autoimmune 
titis is another potential diagnosis, mainly because hepatitis. Furthermore, during the acute phase, there 
atypical forms of this disease, lacking the classical were a few patients with low titers of autoantibodies, but 
autoantibodies (ANA, ASMA, and LKM-I), have been these markers disappeared early during follow-up. This 
described.31 is completely unexpected in autoimmune liver disease. 
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In addition, most patients treated with cortico- 
steroids did not present a biochemical response. 
The spontaneous resolution of the disease observed 
in the majority of our patients strongly argues against 
autoimmune hepatitis, which is almost universally a 
chronic liver disease. 
Above all, the liver biopsies obtained during the 
acute phase were much more suggestive of a virus-related 
hepatitis than hepatitis related to toxic or autoimmune 
hepatic injury. Finally, the clinical and biochemical pre- 
sentations of the disease were similar to those of acute 
hepatitis due to known hepatotropic viruses. 
Remarkably, ferritin levels were significantly higher 
in non-A-E hepatitis cases as compared to acute hepa- 
titis caused by known hepatotropic viruses. The explan- 
ation of this finding is not clear, since neither hepatocyte 
release of ferritin after liver injury nor ferritin being 
released as an acute-phase inflammatory protein was 
indicated, with no correlation with ALT levels being 
detected. 
Iron overload has been documented in some cases 
of chronic viral hepatitis, but the mechanism of iron 
accumulation is poorly understood.32 There is a paucity 
of studies concerning acute hepatitis and iron overload. 
This finding warrants future studies in this field. 
In conclusion, non-A-E hepatitis remains enigmatic 
and not fully understood. The clinical presentation of 
our cases, although quite variable, strongly suggested a 
viral disease with spontaneous resolution in most cases. 
At least 20% of the patients progress to chronic liver 
disease, with variable degrees of liver inflammation. 
Non-A-E hepatitis seems to involve more than one 
disease, perhaps with regional peculiarities, and a vari- 
able prognosis. As suggested by some authors, it could 
be a virus-related disease, although other possibilities, as 
described for cryptogenic cirrhosis, should be ruled 
out 33,34 
The improvement in sensitivity of PCR methods for 
HBV and HCV also warrants further studies, in order to 
define the pathogenic role of these viruses in some cases 
of cryptogenic hepatitis with an unusual serologic 
profile.35,36 
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